Animal models of depression: Are there any?

被引:92
作者
O'Neil, MF [1 ]
Moore, NA [1 ]
机构
[1] Eli Lilly & Co, Lilly Res Labs, Windlesham GU20 6PH, Surrey, England
关键词
disease; models; nervous system;
D O I
10.1002/hup.496
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Simple tests for antidepressant-like activity, such as 5-HTP-induced syndrome or reserpine-induced hypomotility, are often mechanism-based tests, pharmacologically specific for certain known classes of therapeutically successful antidepressant agents. Many of these behavioural assays have been superseded by neurochemical techniques such as in vivo microdialysis. In contrast to these mechanistic-based models, investigators have also endeavoured to reproduce in the laboratory, factors that are believed to precipitate depression in people. It is a strong assumption in this approach that depression is a response to stress. This strategy profiles the consequences of chronic stress particularly psychosocial stress or early life events, in order to reproduce in animals the behavioural signs and pathologies associated with depression. The advances in the social psychological, clinical pathological and new areas such as neuroimaging research offer the possibility of establishing more sophisticated models for depression in animals with a broader range of biomarkers from the immunological and endocrinological to neurochemical and behavioural. Combining these novel insights with more traditional tests of depression may not only increase our understanding of the neurobiology of depression but also afford more precise and predictive preclinical models of depression. The responsiveness of different strains or genetically modified animals to stress is likely to be a key area of study. Furthermore we must look to individual differences in subjects, even within the same strain, to more fully understand why some individuals show pathological responses to stress whereas others appear unaffected. Conversely in validating our models using currently available treatments we must include the concept of non-responders so as not to disregard models that may extend therapeutic possibilities in these patients. Copyright (C) 2003 John Wiley Sons, Ltd.
引用
收藏
页码:239 / 254
页数:16
相关论文
共 136 条
[21]  
BORSINI F, 1988, PSYCHOPHARMACOLOGY, V94, P147
[22]   Does stress damage the brain? [J].
Bremner, JD .
BIOLOGICAL PSYCHIATRY, 1999, 45 (07) :797-805
[23]   CHROMODACRYORRHEA AND REPETITIVE HIND PAW TAPPING - MODELS OF PERIPHERAL AND CENTRAL TACHYKININ NK1 RECEPTOR ACTIVATION IN GERBILS [J].
BRISTOW, LJ ;
YOUNG, L .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1994, 253 (03) :245-252
[24]  
CAIMCROSS KD, 1971, PHARMACOL THERAPEUT, V47, P21
[25]   OLFACTORY PROJECTION SYSTEMS, DRUGS AND BEHAVIOR - REVIEW [J].
CAIRNCROSS, KD ;
COX, B ;
FORSTER, C ;
WREN, AF .
PSYCHONEUROENDOCRINOLOGY, 1979, 4 (03) :253-272
[26]   Variations in maternal care in infancy regulate the development of stress reactivity [J].
Caldji, C ;
Diorio, J ;
Meaney, MJ .
BIOLOGICAL PSYCHIATRY, 2000, 48 (12) :1164-1174
[27]   Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug twenty years since its first publication (vol 57, pg 411, 1995) [J].
Carlsson, A ;
Wong, DT .
LIFE SCIENCES, 1997, 61 (12) :1203-1203
[28]   PHYSIOPHARMACOLOGICAL INTERACTIONS BETWEEN STRESS HORMONES AND CENTRAL SEROTONERGIC SYSTEMS [J].
CHAOULOFF, F .
BRAIN RESEARCH REVIEWS, 1993, 18 (01) :1-32
[29]   Persistent elevations of cerebrospinal fluid concentrations of corticotropin-releasing factor in adult nonhuman primates exposed to early-life stressors: Implications for the pathophysiology of mood and anxiety disorders [J].
Coplan, JD ;
Andrews, MW ;
Rosenblum, LA ;
Owens, MJ ;
Friedman, S ;
Gorman, JM ;
Nemeroff, CB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (04) :1619-1623
[30]   Combining pindolol and paroxetine in an animal model of chronic antidepressant action - can early onset of action be detected? [J].
Cryan, JF ;
McGrath, C ;
Leonard, BE ;
Norman, TR .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 352 (01) :23-28